Try our mobile app

General information

Country: UNITED STATES

Sector: Drug Manufacturers — General

Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products for humans and animals. The Company products are sold in countries around the world. Eli Lilly products include neuroscience, endocrine, anti-infectives, cardiovascular agents, oncology, and animal health products.
Website: lilly.com


  • Good financial results growth rate 44.0% (average between last period year over year growth for revenue and EBITDA), there is acceleration compared to average historical growth rates (27.6%)
  • Dividend yield for the last twelve months 0.7%
  • Free cash flow yield -1.7% (LTM)
  • Share price is 163.2% higher than minimum and 18.7% lower than maximum for the last 3 years
  • The company is overvalued by EV / LTM EBITDA multiple compared to target level (46.4x vs
    )
  • Fundamental value created in LTM (estimate)
  • For the last 3 months insiders sold company shares on $1.7 mln (0.000% of cap.)

Key Financials (Download financials)

Ticker: LLY
Share price, USD:  (-1.3%)780.37
year average price 828.85  


year start price 948.40 2024-07-12

max close price 960.02 2024-08-30

min close price 713.71 2025-05-23

current price 782.45 2025-07-11
Common stocks: 900 605 000

Dividend Yield:  0.7%
FCF Yield LTM: -1.7%
EV / LTM EBITDA: 46.4x
EV / EBITDA annualized: 44.9x
Last revenue growth (y/y):  +45.2%
Last growth of EBITDA (y/y):  +42.9%
Historical revenue growth:  +20.4%
Historical growth of EBITDA:  +34.8%
Target EV / EBITDA (hist percentile):
Express share price potential:
Fundamental value created in LTM:
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 702 805
Net Debt ($m): 35 377
EV (Enterprise Value): 738 182
EBITDA LTM ($m): 15 914
EV / LTM EBITDA: 46.4x
Price to Book: 50.0x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2025-07-10seekingalpha.com

Eli Lilly Comes Out As ADA Winner

2025-07-10youtube.com

The Big 3: AVGO, LLY, UBER

2025-07-10zacks.com

Lilly Down More Than 15% in a Year: Time to Buy, Sell or Hold?

2025-07-09proactiveinvestors.com

Eli Lilly Q2 preview: BofA sees focus on policy risks, obesity pipeline

2025-07-09benzinga.com

Zepbound Powers Eli Lilly's Upbeat Q2 Outlook

2025-07-09prnewswire.com

FDA approves updated label for Lilly's Kisunla (donanemab-azbt) with new dosing in early symptomatic Alzheimer's disease

2025-07-07fool.com

Better Growth Buy: Eli Lilly vs. Viking Therapeutics

2025-07-06fool.com

2 Dividend Growth Stocks to Buy and Hold Forever

2025-07-04barrons.com

Lilly and Novo Are the Kings of Weight-Loss Drugs. The Companies Coming for Their Crowns.

2025-06-28fool.com

Which Stock Will Dominate the Weight Management Market Through 2030?
More information for subscribed users:
detailed calculation of
Potential and Created Value,
website traffic data